<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Camp4 Therapeutics Corporation — News on 6ix</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation</link>
<description>Latest news and press releases for Camp4 Therapeutics Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 07:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/camp4-therapeutics-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683551dd78dffbe2df0e7cd8.webp</url>
<title>Camp4 Therapeutics Corporation</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation</link>
</image>
<item>
<title>Calamos Brings Award-Winning Autocallable Income ETF Strategy to Global Investors with Launch of World's First Autocallable UCITS ETF</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/calamos-brings-award-winning-autocallable-income-etf-strategy-to-global-investors-with-launch-of-worlds-first-autocallable-ucits-etf</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/calamos-brings-award-winning-autocallable-income-etf-strategy-to-global-investors-with-launch-of-worlds-first-autocallable-ucits-etf</guid>
<pubDate>Mon, 27 Apr 2026 07:00:00 GMT</pubDate>
<description>John Koudounis, President and CEO of Calamos, a leading alternatives manager, today announced the launch of the Calamos Autocallable Income UCITS ETF, bringing a proven, successful, award-winning income ETF strategy to investors across Europe, Asia, and the Middle East. With a current annualized weighted average coupon of 14% in the ETF's swap-based index, the Fund is designed to provide high, stable, monthly income through exposure to a laddered portfolio of autocallables, transforming a comple</description>
</item>
<item>
<title>CAMP4 Appoints Michael MacLean to its Board of Directors</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-appoints-michael-maclean-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-appoints-michael-maclean-to-its-board-of-directors</guid>
<pubDate>Tue, 24 Mar 2026 11:00:00 GMT</pubDate>
<description>Appointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorderCAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to tr</description>
</item>
<item>
<title>CAMP4 to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-to-participate-in-upcoming-investor-conferences-2</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-to-participate-in-upcoming-investor-conferences-2</guid>
<pubDate>Fri, 06 Mar 2026 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare C</description>
</item>
<item>
<title>CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-full-year-2025-financial-results-and-corporate-highlights-65</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-full-year-2025-financial-results-and-corporate-highlights-65</guid>
<pubDate>Thu, 05 Mar 2026 21:05:00 GMT</pubDate>
<description>GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritte</description>
</item>
<item>
<title>CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-therapeutics-announces-inducement-grant-210500304</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-therapeutics-announces-inducement-grant-210500304</guid>
<pubDate>Fri, 16 Jan 2026 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a n</description>
</item>
<item>
<title>CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-present-44th-annual-j-130000981</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-present-44th-annual-j-130000981</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conf</description>
</item>
<item>
<title>CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-announces-pricing-30-0-121000695</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-announces-pricing-30-0-121000695</guid>
<pubDate>Thu, 18 Dec 2025 12:10:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of $6.00 per share. The gro</description>
</item>
<item>
<title>CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-gsk-enter-strategic-collaboration-120000162</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-gsk-enter-strategic-collaboration-120000162</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments, in addition to tiered royalties CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targetin</description>
</item>
<item>
<title>CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-therapeutics-announces-inducement-grants-210500902</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-therapeutics-announces-inducement-grants-210500902</guid>
<pubDate>Fri, 12 Dec 2025 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on December 11, 2025 (the “Grant Date”), the Company’s Board of Directors granted non-qualified stock options to p</description>
</item>
<item>
<title>CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-third-quarter-2025-210500785</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-third-quarter-2025-210500785</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders Initiated Good Laboratory Practice (GLP) toxicology studies for CMP-002 in support of a planned clinical trial application for a Phase 1/2 clinical trial expected to initiate as early as 2H 2026 Completed analysis from multiple ascending dose (MAD) portion of the CMP-001 Phase 1 clinical trial demonstrating favorable safety and pharmacokinetics in l</description>
</item>
<item>
<title>CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-therapeutics-initiates-glp-toxicology-120000123</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-therapeutics-initiates-glp-toxicology-120000123</guid>
<pubDate>Wed, 01 Oct 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the initiation of toxicology studies conducted under Good Laboratory Practice (GLP) standards for its lead product cand</description>
</item>
<item>
<title>CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-announces-oversubscribed-private-placement-110000061</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-announces-oversubscribed-private-placement-110000061</guid>
<pubDate>Wed, 10 Sep 2025 11:00:00 GMT</pubDate>
<description>Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $50 million of proceeds to fund the Phase 1/2 clinical trial in patients with SYNGAP1-related disorders, expected to initiate as early as 2H 2026 Doug Williams, Ph.D., to become Board Chair, and Dan Tardiff, Ph.D., elevated to Chief Scientific Officer CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/egenesis-appoints-douglas-williams-phd-and-adam-craig-md-phd-to-its-board-of-directors-2</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/egenesis-appoints-douglas-williams-phd-and-adam-craig-md-phd-to-its-board-of-directors-2</guid>
<pubDate>Tue, 19 Aug 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., August 19, 2025--eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors</description>
</item>
<item>
<title>CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-second-quarter-2025-200500304</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-second-quarter-2025-200500304</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American Society of Gene and Cell Therapy (ASGCT) Annual MeetingInitiating GLP toxicology studies evaluating CMP-SYNGAP-01 in Q3 2025Dosing completed in multiple ascending dose (MAD) cohort 3 of CMP-CPS-001 and data from single ascending dose (SAD) & MAD cohorts expected in Q4 2025 CAMBRIDGE, Mass., Aug. 14, 202</description>
</item>
<item>
<title>CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-presents-translational-data-syngap1-100000367</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-presents-translational-data-syngap1-100000367</guid>
<pubDate>Fri, 16 May 2025 10:00:00 GMT</pubDate>
<description>Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in SYNGAP1 protein levels in relevant brain regions in non-human primates (NHPs) Patient safety and pharmacokinetic data from single ascending dose (SAD) cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers highlighted CAMBRIDG</description>
</item>
<item>
<title>CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-first-quarter-2025-200500450</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-first-quarter-2025-200500450</guid>
<pubDate>Tue, 13 May 2025 20:05:00 GMT</pubDate>
<description>Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral pre</description>
</item>
<item>
<title>CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-present-preclinical-data-urea-203000448</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-present-preclinical-data-urea-203000448</guid>
<pubDate>Mon, 28 Apr 2025 20:30:00 GMT</pubDate>
<description>Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipelin</description>
</item>
<item>
<title>CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-full-2024-financial-200500018</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-reports-full-2024-financial-200500018</guid>
<pubDate>Thu, 27 Mar 2025 20:05:00 GMT</pubDate>
<description>– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025 – Initiation of expansion into Phase 1b clinical trial in female OTC heterozygotes expected in Q2 2025 – Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025 CAMBRIDGE, Mass., Marc</description>
</item>
<item>
<title>CAMP4 Appoints Multiple Industry Veterans to its Board of Directors</title>
<link>https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-appoints-multiple-industry-veterans-120000163</link>
<guid isPermaLink="true">https://6ix.com/company/camp4-therapeutics-corporation/news/camp4-appoints-multiple-industry-veterans-120000163</guid>
<pubDate>Tue, 18 Mar 2025 12:00:00 GMT</pubDate>
<description>With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4’s multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to res</description>
</item>
</channel>
</rss>